Log in to save to my catalogue

Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life Euro...

Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life Euro...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8119503

Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

Publication information

Publisher

Cheshire: Springer Healthcare

More information

Scope and Contents

Contents

Introduction
OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response.
Methods
We performed a retrospective analysis on real-life prospectively collected data in 16 European headache centers. All the cent...

Alternative Titles

Full title

Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8119503

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8119503

Other Identifiers

ISSN

2193-8237

E-ISSN

2193-651X

DOI

10.1007/s40122-021-00253-0

How to access this item